Drug intelligence / Profile preview

liposomal long-acting injectable antibiotic (MRSA)

Development stage: Preclinical
Lead developer: Akagera Medicines
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Injectable

Overview

This is a preclinical-stage, long-acting injectable (LAI) antibiotic formulation being developed by Akagera Medicines Africa for the treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) infections. The therapy utilizes a liposomal nanoparticle delivery system designed to encapsulate a small molecule antibiotic. A key feature of this formulation is its design for phagocytosis-mediated uptake into macrophages, which allows for targeted delivery and sustained release of the antibacterial agent. This approach aims to improve treatment adherence and efficacy against persistent MRSA infections by maintaining therapeutic drug levels over an extended period.

Other names: Akagera MRSA antibioticLong-acting injectable antibiotic (MRSA)liposomal long-acting injectable antibiotic (methicillin-resistant staphylococcus aureus)-Akagera Medicines Africa-Long-Acting Injectable (LAI)-liposomal nanoparticles-small molecule formulation-injectable-MRSA (Methicillin-Resistant Staphylococcus aureus)

Beyond the preview

Go deeper on liposomal long-acting injectable antibiotic (MRSA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on liposomal long-acting injectable antibiotic (MRSA).

Explore the full profile